Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical needs. In an interview with AlphaStreet, Kairo Pharma’s chief executive officer, Dr. John Yu, shared valuable insights into the company’s approach to cancer treatment and the vision driving its work. Dr. John is … Read more